Treat and extend regimens with intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion

Treat and extend regimens with intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion - Treat and extend intravitreal aflibercept for branch retinal vein occlusion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027005

Enrollment

Registered

2019-04-17

Start date

2017-04-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

branch retinal vein occlusion

Interventions

intravitreal aflibercept PRN intravitreal aflibercept treat and extend

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were over 20 years of age with BCVA of 0.1 and 1.0 (Snellen equivalent) and naive branch retinal vein occlusion and below 3 months disease duration and below 5DA nonperfusion area.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had received treatment such as glaucoma or vitreous surgery and cataract surgery within 3 months; and if they had diabetic retinopathy or central retinal vascular occlusion.

Design outcomes

Primary

Measure	Time frame
best-corrected visual acuity and retinal sensitivity at 12 months	—

Secondary

Measure	Time frame
foveal retinal thickness at 12 months	—

Countries

Japan

Contacts

Public ContactTsutomu Sakai

Jikei daisan hospital Ophthalmology

tstmski@jikei.ac.jp0334801151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026